We validated the in vivo suppressive effect of CCL20-NAb on the CCL20/CCR6 axis in EMs mice model, and our data suggested that CCL20-NAb inhibited the growth of lesions. This evidence concerns the gene CCR6 and eosinophilia-myalgia syndrome.